CoChat

A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer

Open access
Chalasani, Pavani, Marron, Marilyn, Roe, Denise, Clarke, Kathryn, Iannone, Maria, Livingston, Robert B., Shan, Joseph S., Stopeck, Alison T. · 2015 · Cancer Medicine
Cited by 45

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS is externalized on cells in the tumor microenvironment when exposed to hypoxia and/or other physiological stressors. On attaching to PS, bavituximab is thought to promote antitumor immunity through its effects on PS receptors in monocytes, and myeloid‐derived suppressor cells, as well as trigger antitumor effects by inducing an antibody‐dependent cellular cytotoxicity on tumor‐associated endothelial cells. We conducted a phase I clinical trial of bavituximab in combination with paclitaxel in patients with HER2‐negative metastatic breast cancer. Patients were treated with weekly paclitaxel (80 mg/m 2 for 3/4 weeks) and weekly bavituximab (3 mg/kg for 4/4 weeks). Correlative studies included the measurement of circulating microparticles, endothelial cells, and apoptotic tumor cells by flow cytometry. Fourteen patients with metastatic breast cancer were enrolled; all were evaluable for toxicity and 13 were evaluable for response. Treatment resulted in an overall response rate (RR) of 85% with a median progression‐free survival (PFS) of 7.3 months. Bone pain, fatigue, headache, and neutropenia were the most common adverse effects. Infusion‐related reactions were the most common adverse event related to bavituximab therapy. Correlative studies showed an increase in the PS‐expressing apoptotic circulating tumor cells in response to bavituximab, but not with paclitaxel. No changes in the number of circulating endothelial cells or apoptotic endothelial cells were observed with therapy. Platelet and monocyte‐derived microparticles decreased after initiation of bavituximab. Bavituximab in combination with paclitaxel is well tolerated for treatment of patients with metastatic breast cancer with promising results observed in terms of clinical RRs and PFS. The toxicity profile of bavituximab is notable for manageable infusion‐related reactions with no evidence for increased thrombogenicity. Recent preclinical data suggest that bavituximab can also promote antitumor immune activity that should be explored in future clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.447

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Mechanisms of Thrombus Formation

    Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926 · cited 1×

    “P-selectin glycoprotein ligand-1) that can be activated on exposure to injured endothelium leading to coagulopathy and hypercoagulability [27].”
    Background

Show all 1 references

Cited by

See all 45

Metadata

Authors
Chalasani, P., Marron, M., Roe, D., Clarke, K., Iannone, M., Livingston, R. B., Shan, J. S., & Stopeck, A. T.
Venue
Cancer Medicine
Publisher
Wiley
Published
2015-03-31
Volume
4
Issue
7
Pages
1051-1059
ISSN
2045-7634 (ISSN-L)
OpenAlex
W2093827776
Cited by
45
References
1
FWCI
1.67
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. https://app.cochat.ai/papers/10.1002/cam4.447
The paper
Chalasani, P., Marron, M., Roe, D., Clarke, K., Iannone, M., Livingston, R. B., Shan, J. S., & Stopeck, A. T. (2015). A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Medicine. https://doi.org/10.1002/cam4.447

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.